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Ileana Mardare 43, Dmitry Meshkov 44, Tanja Novakovic 45, Jurij Fürst 46, Dominik Tomek 47,
Corrine Zara 48, Eduardo Diogene 49, Johanna C. Meyer 4, Rickard E. Malmström 50,
Björn Wettermark 50,51, Zinhle Matsebula 52, Stephen Campbell 53,54 and Alan Haycox 2
1 Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom, 2Health
Economics Centre, University of Liverpool Management School, Liverpool, United Kingdom, 3Division of Clinical
Pharmacology, Karolinska Institute, Karolinska University Hospital Huddinge, Stockholm, Sweden, 4 School of Pharmacy,
Sefako Makgatho Health Sciences University, Pretoria, South Africa, 5Mechanism of Coordinated Access to Orphan
Medicinal Products (MoCA), Brussels, Belgium, 6 Ecorys, Rotterdam, Netherlands, 7Department for Health Evidence,
Radboud University Medical Center, Nijmegen, Netherlands, 8Department of Drug Management, Faculty of Health Sciences,
Jagiellonian University Medical College, Krakow, Poland, 9Division of Health Policy and Insurance Research, Department of
Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, United States,
10 EURORDIS-Rare Diseases Europe, Paris, France, 11 Institute of Translational Medicine, University of Liverpool, Liverpool,
United Kingdom, 12HCD Economics, The Innovation Centre, Daresbury, United Kingdom, 13 KU Leuven Department of
Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, 14Department of Pharmacology, College of Pharmacy,
Hawler Medical University, Erbil, Iraq, 15Global Health and Development Group, Imperial College, London, United Kingdom,
16Department of Pathology, Forensic Medicine and Pharmacology, Faculty of Medicine, Institute of Biomedical Sciences,
Vilnius University, Vilnius, Lithuania, 17NHS Lothian, Edinburgh, United Kingdom, 18 IQVIA, Brussels, Belgium, 19Department
of Pharmacy, Faculty of Medicine, University of Medicine, Tirana, Albania, 20Hauptverband der Österreichischen
Sozialversicherungsträger, Vienna, Austria, 21Department of Biomedical Sciences, Faculty of Medicine, University of
Botswana, Gaborone, Botswana, 22Department of Social Pharmacy, College of Pharmacy, Federal University of Minas
Gerais, Av. Presidente Antônio Carlos, Belo Horizonte, Brazil, 23 SUS Collaborating Centre – Technology Assessment &
Excellence in Health (CCATES/UFMG), College of Pharmacy, Federal University of Minas Gerais. Av. Presidente Antônio
Carlos, Belo Horizonte, Brazil, 24Department of Social Pharmacy and Pharmacoeconomics, Faculty of Pharmacy, Medical
University of Sofia, Sofia, Bulgaria, 25Health Insurance Organisation (HIO), Nicosia, Cyprus, 26 State Agency of Medicines,
Tartu, Estonia, 27 IRDES, Paris, France, 28Wissenschaftliches Institut der AOK (WIdO), Berlin, Germany, 29 EOPYY-National
Organization for the Provision of Healthcare Services, Athens, Greece, 30 School of Economics and Political Science,
University of Athens, Athens, Greece, 31Department of Health Services, Ministry of Health, Reykjavík, Iceland,
32 Pharmaceutical Drug Department, Azienda Sanitaria Locale of Verona, Verona, Italy, 33Department of Pharmacology
and Pharmacognosy, School of Pharmacy, University of Nairobi, Nairobi, Kenya, 34Division of Biology and Public Health,
Mokwon University, Daejeon, South Korea, 35UBT - Higher Education Institute, Prishtina, Kosovo, 36Department of
Pharmacology and Therapeutics, Faculty of Health Sciences, University of Namibia, Windhoek, Namibia,
37Department of Pharmacology and Therapeutics, Ekiti State University, Ado-Ekiti, Nigeria, 38Norwegian Institute of Public
Health, Oslo, Norway, 39 Agency for Health Technology Assessment and Tariff System (AOTMiT), Warsaw, Poland, 40HTA
Consulting, Cracow, Poland, 41Ministry of Health and Social Welfare, Banja Luka, Bosnia and Herzegovina,
Godman et al. Access to New Medicines
42Department of Social Pharmacy, Faculty of Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina,
43 Public Health and Management Department, Faculty of Medicine, “Carol Davila”, University of Medicine and Pharmacy
Bucharest, Bucharest, Romania, 44National Research Institution for Public Health, Moscow, Russia, 45 ZEM Solutions,
Belgrade, Serbia, 46Health Insurance Institute, Ljubljana, Slovenia, 47 Faculty of Medicine, Slovak Medical University in
Bratislava, Bratislava, Slovakia, 48Drug Territorial Action Unit, Catalan Health Service, Barcelona, Spain, 49 Vall d’Hebron
University Hospital, Fundació Institut Català de Farmacologia, Barcelona, Spain, 50Department of Medicine Solna, Karolinska
Institutet and Clinical Pharmacology Karolinska University Hospital, Stockholm, Sweden, 51Department of Healthcare
Development, Stockholm County Council, Stockholm, Sweden, 52 Raleigh Fitkin Memorial Hospital, Manzini, Swaziland,
53Division of Population Health, Health Services Research and Primary Care, Centre for Primary Care, University of
Manchester, Manchester, United Kingdom, 54NIHR Greater Manchester Patient Safety Translational Research Centre, School
of Health Sciences, University of Manchester, Manchester, United Kingdom
Introduction: There is continued unmet medical need for new medicines across
countries especially for cancer, immunological diseases, and orphan diseases. However,
there are growing challenges with funding new medicines at ever increasing prices along
with funding increased medicine volumes with the growth in both infectious diseases
and non-communicable diseases across countries. This has resulted in the development
of new models to better manage the entry of new medicines, new financial models
being postulated to finance new medicines as well as strategies to improve prescribing
efficiency. However, more needs to be done. Consequently, the primary aim of this paper
is to consider potential ways to optimize the use of new medicines balancing rising
costs with increasing budgetary pressures to stimulate debate especially from a payer
perspective.
Methods: A narrative review of pharmaceutical policies and implications, as well
as possible developments, based on key publications and initiatives known to the
co-authors principally from a health authority perspective.
Results: A number of initiatives and approaches have been identified including new
models to better manage the entry of new medicines based on three pillars (pre-, peri-,
and post-launch activities). Within this, we see the growing role of horizon scanning
activities starting up to 36 months before launch, managed entry agreements and post
launch follow-up. It is also likely there will be greater scrutiny over the effectiveness
and value of new cancer medicines given ever increasing prices. This could include
establishing minimum effectiveness targets for premium pricing along with re-evaluating
prices as more medicines for cancer lose their patent. There will also be a greater
involvement of patients especially with orphan diseases. New initiatives could include
a greater role of multicriteria decision analysis, as well as looking at the potential for
de-linking research and development from commercial activities to enhance affordability.
Conclusion: There are a number of ongoing activities across countries to try and fund
new valued medicines whilst attaining or maintaining universal healthcare. Such activities
will grow with increasing resource pressures and continued unmet need.
Keywords: managed entry, health policy, pharmaceuticals, financing, cancer, orphan diseases, new models
INTRODUCTION
Spending on medicines is a concern across all countries
due to changing demographics and lifestyles leading to
increased medicine use, stricter targets for treating patients,
rising patient expectations and the continued launch of new
premium priced medicines (1–6). The costs of medicines are a
particular issue in low and middle income countries (LMICs)
where they can account for up to 70% of total healthcare
expenditure (7, 8), exacerbated by high and growing prevalence
of non-communicable diseases (NCDs) such as diabetes and
hypertension. The growing prevalence of NCDs in LMICs leads
to issues of affordability (9), with funding of medicines for
patients with cancer and immune diseases such as rheumatoid
arthritis a particular challenge due to their costs (10–13). High
income countries are also struggling to fund new premium priced
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medicines in all or some populations (3, 14). This situation will
worsen with continuing unmet need (4) leading to continued
debates regarding the possible funding of new high priced
medicines in different disease areas.
Total expenditure on medicines among OECD countries in
2015 was over US$800 billion and rising as a result of appreciable
increases in expenditure on new medicines for hepatitis C and
in oncology (15). Concerns with the potential budget impact
of second generation direct acting antivirals (DAAs) resulted in
restrictions on their use despite their undoubted effectiveness
(16–19). There were also intense price negotiations across
countries with for instance the authorities in France initially faced
with the cost of sofosbuvir at 756 times its cost of production,
i.e., potentially over 99.8% gross profit, before negotiations (20).
However, prices in some countries, e.g., Egypt, were discounted
up to 99% from the US prices to support affordability (16, 17, 20).
Overall, prices were substantially lower for second generation
DAAs in LMICs to help with affordability (21).
The increased expenditure on cancer medicines has been
augmented by prices for new cancer medicines rising by
up to 10-fold during the last decade (22, 23). As a result,
expenditure on medicines for patients with cancer now dominate
pharmaceutical expenditure in developed markets (24). The
increasing prevalence of patients with cancer, coupled with rising
prices (25–28), has seen world-wide sales of medicines for cancer
reach $107billion in 2015, an increase of 11.4% since 2014 (29).
Expenditure on cancer medicines will rise further with new
cancer cases anticipated to rise to 21.4 million per year by 2030
(22, 30) coupled with the appreciable pipeline of new potential
premium priced oncology drugs with more than 500 companies
actively pursuing new oncologymedicines in over 600 indications
(29).
The increasing expenditure on new premium priced
medicines in recent years, including those for cancer, is despite
their questionable therapeutic value, with most new medicines
revealing limited or no health gain vs. existing therapies when
appraised by independent drug information journals (Table 1)
(33–37).
This is certainly the case for new cancer medicines as there
is limited health gain for most alongside uncertain evidence
(25, 38–42). However, high prices have been facilitated by
pharmaceutical companies seeking orphan status for their new
cancer medicines. This is despite the cost of goods for a number
of new cancermedicines as low as 1% of originator prices (43, 44).
There have also been concerns with funding for new
medicines for patients with orphan diseases given increasing
prices and uncertain evidence (33, 34, 45, 46), again exacerbated
by the emotive nature of the disease area (37). In view of the
number of medicines for orphan diseases currently available
and in development, it is likely that global spending on orphan
medicines will reach US$178billion per year by 2020 (47),
equalling the amount spent on medicines for patients with
cancer. There may though be some overlap with a number of new
antineoplastic medicines designated as orphan status. However,
concerns with the requested prices for medicines for orphan
diseases, and their potential budget impact, has to be balanced
against incentives for pharmaceutical companies to develop new
TABLE 1 | Percentage ratings for new medicines and new indications introduced
in France between 2010 to 2015 [Adapted from (2, 31, 32)].
Prescrire ratings/criteria 2010 2011 2012 2013 2014 2015
Total number of new
medicines/new indications
97 92 82 90 87 87
Innovative medicine/ real
therapeutic advance
1% 0% 1% 0% 3% 3%
Offers an advantage over
current standards
3% 3% 4% 7% 6% 6%
Possibly helpful, minimal or no
clinical advantage compared
to existing standard
treatments
73% 72% 68% 66% 58% 67%
Others including not being
seen as acceptable due to
known or suspected serious
adverse events as well as
uncertain, unproven or limited
effectiveness. In addition,
judgement reserved regarding
the possible level of
innovation due to insufficient
data available
23% 25% 27% 27% 33% 24%
medicines to address unmet need (48, 49). We are also aware
that the prices for a number of medicines for orphan diseases are
sustainable (50), and that sales of medicines for orphan diseases
can be limited, e.g., sales of Pfizer’s Elelysor (taliglucerase
alfa) for type 1 Gaucher disease had a net revenue of only
US$48million in 2016 (47). We have also seen the establishment
of European ReferenceNetworks for patients with rare diseases to
accelerate research in the area of orphan diseases, which coupled
with a greater role of patients and registries, could help with
appropriate pricing models (47, 51, 52). However, this remains
to be seen.
Adaptive pathways have also been proposed to accelerate
the introduction of innovative medicines in Europe (53, 54).
However, there are considerable concerns among European
payers in this regard, and these will continue.
The increasing impact of personalized medicine within a
number of therapeutic fields is also a major challenge with regard
to the developmental chain for new medicines. This includes
evidence generation through clinical research, optimization of
novel treatment approaches, adaptation of tools for assessment,
reimbursement mechanisms, costs, and monitoring of outcomes
(55–58). For example, the use of health technology assessments
(HTA) to reveal the added values of treatments in personalized
medicine is challenging, which in turn may well have an impact
on reimbursement processes. There are also concerns with the
funding of new gene therapies at ∼US$1.3million per dose,
although limited sales to date (47).
Concurrent with these developments, we have seen health
authorities instigate educational and other activities as part of
developing a comprehensive model to better manage the entry
of new medicines where there have been concerns with their
potential safety and/ or expenditure in routine clinical care. This
was the case with dabigatran with increased acquisition costs
over warfarin coupled with concerns with potentially excessive
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bleeding and deaths arising from inappropriate use, exacerbated
by issues with the commercial activities of the company
(3, 59, 60). There was typically no excessive bleeding and no
excessive deaths in countries and regions that had instigated
educational and other activities to enhance the appropriate use
of dabigatran post launch (59, 61).
We are also seeing the growth in managed entry agreements
(MEAs) and other mechanisms to lower the price of new
medicines to enhance their chances of reimbursement (62–66). In
addition, the development of multiple criteria decision analysis
(MCDA) tools for valuing new medicines especially those for
orphan diseases (2, 67–72).
Alongside this, health authorities across countries have
instigated a variety of measures and initiatives to improve
prescribing efficiency to release valuable resources. These include
measures to direct physicians toward prescribing well proven and
effective medicines, enhance the prescribing of generics versus
originators and patented products in a class and biosimilars,
as well as actively pursue disinvestment of technologies where
pertinent (73–79). Strengthening pro-generic and biosimilar
policies, as well as increasing transparency, are especially
important in LMICs to enhance access to medicines (80, 81).
The prescribing of generics is growing across countries as more
originators lose their patents, helped by prices of generics as low
as 2% of originator prices (82–85). However, we are aware that
any quality, safety and efficacy concerns with generics need to be
addressed before savings can be fully realized (86, 87).
Given ongoing concerns and barriers to the funding of new
medicines with increasing resource pressures, the aim of this
paper is to consider potential ways to optimize the use of
new medicines balancing rising costs with increasing budgetary
pressures. This includes potential approaches to the funding of
research and development (R & D) for new medicines. The
situation in LMICs can be more challenging with issues of
affordability and access even to essential medicines. As a result,
we hope to stimulate future debates in this crucial area.
METHODS
We present a narrative review of pharmaceutical policies and
implications, as well as possible developments, based on key
publications and initiatives known to the co-authors who are
experts in this research and practice area. This is principally
from a health authority perspective as many of the co-authors
are senior level decision makers and advisers in their country.
We have used this approach before in a number of previous
publications to provide direction and stimulate debate (2, 33, 55,
75, 88–91).
We do not discuss specifically pricing and reimbursement
policies across countries as this has been undertaken by others
(34, 92–94). We also do not discuss ongoing initiatives to
increase the prescribing of low cost generics or biosimilars, or
disinvestment practices, as these initiatives have also already
been covered by the co-authors and others in a number of
published studies (75, 76, 78, 79, 95–98). We also do not discuss
issues of adherence to medicines, which is of particular concern
with medicines for patients with NCDs, with non-adherence
negatively impacting on morbidity, mortality and costs (99–104),
as these issues are outside the scope of this paper. We are also
aware of access programmes especially in African countries for
key medicines for infectious diseases and NCDs (9, 105, 106).
However, again this is outside the scope of this paper although
this will be briefly mentioned when discussing different pricing
approaches as well as potential ways forward.
RESULTS—ONGOING INITIATIVES
There are a number of ongoing approaches to enhance the
funding for new valued medicines especially among higher
income countries given ongoing budgetary constraints. These
include developing new models to optimize their managed entry
including issues of MEAs and post launch registries; developing
and testing MCDA approaches; and developing new financing
approaches. These will now be discussed in detail building on
recent publications to give future direction with a particular
emphasis on medicines for cancer and orphan diseases (34, 94,
107–111).
New Models to Optimize the Managed
Entry of New Medicines
Payers and their advisers across Europe andwider have developed
new models to optimize the managed entry of new medicines
in response to ever increasing costs of new medicines, which
build on initial initiatives in Stockholm, Sweden, and across
Europe (112, 113). The models have subsequently been refined
based on activities surrounding the launch of dabigatran to
help prevent potential excessive bleeding (Figure 1) (3, 59), with
further iterations since then. These models are typically based on
three pillars: pre-, peri-, and post launch activities (3, 33, 34, 114–
116).
We are aware that there is appreciable variation in the
uptake and utilization of new medicines across countries as
seen for instance with physicians in the UK typically more
conservative in adopting new medicines than colleagues in
Italy, Spain or the US (117–120). Generally, critical factors
in the uptake and utilization of new medicines across sectors
include issues of involvement in clinical trials, influence and
impact of drug and therapeutic committees (DTCs), cost of
the new medicines to hospitals including potential budgets and
any discounts, as well as pharmaceutical industry and patient
pressures (115, 117, 121–128). Introducing a more structured
approach (Figure 1) seeks to address a number of these issues and
concerns.
Pre-launch activities include horizon scanning and budgetary
planning, with peri-launch activities including assessing the role
and value of new medicines using robust methodologies as
well as appraising proposed MEAs (34, 115, 129). Post launch
activities including evaluating the effectiveness and safety of
new medicines in routine clinical practice via registries and
other approaches as well as assessing prescribing against agreed
guidelines (Figure 1). The following sub-sections contain further
details.
Pre-launch Activities
Pre-launch activities include horizon scanning for newmedicines
to prepare for the future. Horizon scanning for medicines is
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FIGURE 1 | Ongoing model to optimize the managed entry of new drugs across Europe incorporating national and regional stakeholder groups (Reproduced with
kind permission of Frontiers in Pharmacology) (3, 59).
defined as “identifying new medicines or new uses of existing
medicines that are expected to receive marketing authorization
from the Regulatory Authority in the near future and estimating
their potential impact on patient care” (113, 130, 131), with
activities growing across countries and regions (131–137). This
includes recent proposals for cross country collaboration in
Horizon Scanning (137). A recent publication from Sweden
has shown good sensitivity for such analyses especially in the
oncology/immunomodulating areas (138).
Horizon scanning activities can include budget forecasts in all
or some populations to help fund their utilization within agreed
budgets (115, 116, 136, 139). They typically consist of a number
of sequenced approaches (Figure 2).
Typical prioritization criteria for selecting which medicines to
review as part of horizon scanning activities include (116, 133,
136, 140):
• Number of potential patients for the newmedicine and disease
severity
• Intended use of the new medicine, i.e., add-on to existing
medicines, a replacement for existing treatments or an
innovative approach
• Likely health gain of the new medicine vs. existing standards
including any potential safety issues, i.e., potential to critically
improve patient outcomes
• Current clinical development status, i.e., Phase II or III
• Estimated budget impact based on likely costs—especially if
likely comparators will soon lose their patent
• Potential for off-label use and its budget impact
• Potential to result in re-organization of healthcare for the
disease area
• Possible high media/ public interest.
Horizon scanning activities often start up to 24 to 36 months
before likely European Medicines Agency (EMA) marketing
authorization. They include providing data to regional and
national payers on the findings from Phase II studies and
ongoing Phase III trials, with more complete data provided
nearer marketing authorization by regulatory agencies such as
the EMA (133, 136, 137). However, providing horizon scanning
data just before marketing authorizationmay be too late for some
healthcare systems to effectively react with increased budgets for
new valued medicines (142).
We are also seeing the growth in budget impact analyses
(BIAs) to help estimate the potential financial implications of
new technologies and their possible impact on future spending
(116, 143). The key components of any BIA should include the
following: (i) the budget holders’ perspective; (ii) the defined time
horizon for the analysis, e.g., up to 36 months post launch; (iii)
clear identification of the setting; (iv) budget estimates expressed
as undiscounted cost differences between any new medicine and
the current situation; (v) estimates taking into account potential
trade-offs in healthcare resources based on possible variations
in the effectiveness of the new medicine; and (vi) sensitivity
analyses taking into account the uncertainty surrounding future
care (116, 144). Drug utilization studies using patient level data
enhance the robustness of forecasted budgets through reducing
uncertainty as seen for instance in Brazil when documenting the
cost of atypical antipsychotics in the public healthcare system
(145). Robust patient level data is also used to develop forecasts
for the potential spend on new medicines in Stockholm County
Council, Sweden, helped by expert groups and interaction with
pharmaceutical companies (136, 139).
It is increasingly recognized that a more integrative approach
is needed in the future to enhance the usefulness of peri-launch
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FIGURE 2 | Sequenced approaches for Horizon Scanning activities [adapted from (116, 133, 140, 141)].
activities, including increased use of HTA techniques, which
will require new skills (142). In addition, considering smart
data systems and greater international collaboration to improve
the efficiency and usefulness of horizon scanning activities and
outputs (142).
Independent willingness-to-pay and other preference
elucidation studies can also be conducted at this time to help
authorities in their pricing negotiations, especially if such data is
taken into account during pricing negotiations as seen currently
in Brazil (146, 147).
The development of any potential quality indicators to
improve the prescribing of the new medicine post launch should
also ideally be considered pre-launch and not several years after
launch, which has typically been the case in the past (148). The
same applies to the development of any patient registry for new
medicines especially for patients with orphan diseases (3, 47),
which can be part of ongoing measures to enhance physician
adherence to any prescribing guidelines. Specific biomarkers to
better target patients for new therapies should also be highlighted
given the growth in pharmacogenomics (55).
Peri Launch
Countries have typically adopted different approaches to the
pricing and reimbursement of new medicines (34, 92, 94, 141,
149, 150). These can be classified into those that first assess the
level of innovation of new medicines against existing standards
before negotiating prices, such as Austria, France, and Germany
(34, 92, 115, 151, 152), as opposed to those countries that
base reimbursement and funding decisions on economic criteria
such as cost/quality adjusted life year (QALY), with or without
threshold levels, as seen for instance in Belgium, Sweden and the
United Kingdom (33, 34, 92, 110, 153, 154). Other countries apart
from European countries that also increasingly include economic
criteria in their pricing and reimbursement decision making
include Australia, Brazil, Canada, Korea, and New Zealand
(2, 92, 146, 155, 156). Currently though, only a minority of
countries such as Poland, Slovakia, and the United Kingdom use
economic principles to set threshold levels (63, 92), although
some countries such as Belgium provide guidance (110). There
are suggestions by some authors that any proposed levels should
be lowered for long term sustainability (157). However, the lack
of standard methodologies for determining possible thresholds,
with the WHO recently stating it does not recommend three
times GDP per capita as being relatively cost effective (158),
appears to have provided manufacturers with a means to justify
higher prices (159).
Whichever method is used, all incorporate approaches to
assess the value of new medicines based on HTA principles
and techniques with variable levels of uncertainty, with the
concept of value based pricing (VBP) increasingly utilized (34,
66, 141, 160). However, whilst VBP is a well-established concept,
there is no universal definition and its implementation has
been challenging (129, 158, 161, 162). Having said this, VBP
typically means the use of strategies designed to link prices of
a perceived medicine with its perceived value (153, 158, 163),
with issues such as the cost-effectiveness of a new medicine
just one of the key considerations for reimbursement alongside
issues of affordability and budget impact (66, 158, 161). Such
considerations are particularly important in LMICs (164).
As a result of increasing resource pressures, we are likely
to see the continued role of robust comparative effectiveness
analysis along with BIAs in reimbursement decisions (158),
especially with limited perceived innovation with most new
medicines (Table 1). This will also require more independent
BIAs being performed to help assess issues of affordability of
new medicines given concerns with bias if BIAs are performed
by commercial organizations (165). In addition, acknowledging
differences between payers and companies, with companies
typically seeking prices that may not be consistent with VBP
on the basis that their new medicine, such as those for cancer
and orphan diseases, should be treated differently (36, 49, 153).
These concerns can be eased by companies providing data
to suggest in which sub-populations their new medicine will
provide most benefit, which should be aided by the increasing
availability of biomarkers (55, 166), as well as more closely
aligning requested prices with the additional health gain of their
newmedicine (25, 39, 49). The alternative is for healthcare sectors
to impose restrictions themselves on the use of new and expensive
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medicines to stay within agreed budgets (115), which may be
more arbitrary potentially adversely impacting on care provision.
Alongside this, prices and/ or discounts for patented medicines
will have to be increasingly re-evaluated as comparators become
available as either low cost generics or biosimilars.
We are also likely to see increased cross border and
regional collaboration among countries to enhance their pricing
negotiations (46, 167–170). The number of MEAs, also called
risk sharing arrangements, will also grow with pharmaceutical
companies wishing reimbursement for their new medicines (65).
This is because reimbursement is essential in most countries
otherwise there will be limited funding and utilization of any new
medicine.
There is also an ongoing proposal from the European
Commission to strengthen joint cooperation on HTA beyond
2020 (171–173). Whilst such an approach is welcome to reduce
duplication of activities, which is especially important among
European countries with limited resources, a number of concerns
have been identified with the proposal as originally set out. These
include making sure that any European Coordination Group
has the final say on any joint assessment report, which includes
safety data and relative effectiveness assessments, rather than
the Commission (as recommended in the proposal). This is
important since there are concerns with pushing for acceptance
of early assessments with greater uncertainty with available
data extending from concerns with adaptive pathways (53,
54). In addition, there must be continued flexibility to allow
national decision makers to be actively involved when using any
joint report for their reimbursement decisions given ongoing
differences in the availability and affordability of medicines
between European countries (171).
Other ways to influence prices of medicines, and hence their
affordability, include revising wholesaler and pharmacy mark-
ups where needed (33, 174). Wholesaler margins typically vary
between 2 and 8% of the pharmacy retail price in Europe,
although mark-ups as high as 24% have been seen for a small
number of medicines (174). For instance, the mark-up in Croatia
was 8.5% of ex-factory prices, and in Greece there were up to 130
wholesalers at one stage vs. for instance twenty in the UK and
three in Denmark with mark-ups as high as 7.8% before falling
to 5.4% (175, 176). Pharmacy mark-ups have typically ranged
between 18 and 25% among European countries, although mark-
ups have been as low as 12% and as high as 50% (174). Whether
a mark-up is based on a percentage of the base price (which can
result in unduly high or low absolute amounts) or a flat fee, or
a combination of both, is better, is an ongoing discussion across
countries. Given the current political situation within countries,
this has to be decided at the national level by each Member
State in the European Union and other countries. Such debates
are increasing especially with the continued launch of expensive
new medicines in ambulatory care coupled with the increasing
availability of low cost generics.
Managed entry agreements
MEAs can be divided into (a) financial schemes typically
involving discounts, rebates, or price volume agreements and
(b) performance based schemes including outcome guarantee
schemes (63, 91, 110, 150). Schemes involving (usually
confidential) discounts, rebates, or price: volume agreements,
are increasingly seen in practice as they are easier to administer
(150, 155, 177). Outcome or performance based agreements
are seen as more problematic since they increasingly require
robust and sophisticated systems to collect the data and many
confounders may influence the outcomes in real life (63, 66, 110).
This can potentially be addressed through clear definitions of the
data to be collected, open and agreed standards for outcomes
to be measured, clear and transparent decision making rules,
openness of the information collected, as well as clarifying early
in the process who owns and funds any patient registries that
will be used (108). Such schemes can be linked to coverage
with evidence schemes; however, these can also be problematic
in Europe with limited incentives for companies to collect
additional data and difficulties with delisting newmedicines from
reimbursement lists based on their value rather than safety (108,
110). Overcoming the latter may well require strengthening of
health authorities’ abilities to uphold negative funding decisions
(108). In addition, in the case of oncology, performance based
schemes have typically been based on surrogate markers rather
than clinically relevant outcome measures (178). This can be
a concern if there is no clear link between the surrogate
markers used and improved overall survival, which is a key
goal of treatment (25, 179, 180). As a result, we are now
seeing disillusionment and an ensuing decline in the use of
this particular type of MEA (181). However, they have proven
beneficial under the right circumstances (182), and we may see
their use increasing again as the use of “real world” evidence
generation grows (66, 183, 184). Outcome based schemes may
also achieve lower prices in practice than indication based pricing
schemes with their many challenges (185).
Overall despite these concerns, we are likely to see continuing
growth in MEAs to enhance access to new medicines, especially
new oncology medicines, as countries struggle to stay within
budgets with ever increasing prices (62, 65, 107, 150). However,
there is increasing agreement that MEAs should not become the
norm for introducing new medicines (111). The need for MEAs
is symptomatic of unsustainable prices and their use fosters a
lack of transparency. Overall, new medicines should be priced
at sustainable levels for all key stakeholder groups, and the use
of MEAs should be the exception rather than the norm aimed
particularly for new medicines with anticipated high expenditure
and uncertain longer-term clinical benefits (111).
Having said this, experience in implementing MEAs does
vary substantially across Europe. It is recognized that there
is considerable scope for countries to share their experiences
recognizing though that publications assessing such schemesmay
be limited due to data protection concerns (63, 150). It is essential
going forward that all key stakeholder groups should also ask
themselves whether confidential discounts within public health
care systems should be continued (63), and whether legislative
measures could be introduced to force companies to disclose
discount levels (167). This is important as it is not clear who
is really benefiting from existing MEA schemes especially in
countries where there are substantial co-payments for medicines
based on list rather than discounted prices (63). In the future,
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countries need to establish clear objectives for any agreed MEA
as well as seek to introduce a monitoring framework alongside
assessing the financial burden of their implementation. Such
information will help health authorities fully evaluate the role of
MEAs in the future.
Indication-based pricing for new medicines
We are aware that there are proposals to incentivise
pharmaceutical companies to invest in ongoing research
for new indications for existing treatments to reduce the
reliance on new medicines (186). There have also been calls
for indication specific pricing to expand the use of existing
medicines (187, 188). However, there are concerns about the
availability of robust information systems to track this, similar to
concerns with outcome based MEAs (188).
In addition, some companies already promote the off-label use
of their medicines, as well as increase the number of indications
post launch, to extend their patent life, and hence profitability
(189–191). This is after they have secured optimal prices for their
new medicine based on the greatest value in a given population.
Extending the patent life has been enhanced by the issuing of
supplementary protection certificates (SPCs) (192).
However, such activities can cause concern especially in
countries such as the UKwith high international non-proprietary
name (INN) prescribing once the first indication loses its patent.
Doctors in the UK were threatened with legal action if they
prescribed pregabalin by INN name for neuropathic pain rather
than the originator, with the neuropathic pain indication still
patent protected (190). This is because high INN prescribing is
routine in the UK apart from a minority of situations (193, 194).
These issues and concerns will need to be resolved before
indication-based pricing becomes a realistic option. However,
this has to be balanced against decreasing times for patent
protection with stricter regulatory requirements for new
medicines which SPCs can help address (192).
Differential pricing between countries as well as cross border
collaboration with pricing negotiations
An alternative to confidential discounts to enhance the chances
of reimbursement for new premium priced medicines, especially
among LMICs where affordability is an issue, is variable pricing
based on countries’ ability to pay (111, 195). The European
Pharmaceutical Industry Federation (EFPIA) recently considered
the possibility of tiered pricing for European countries struggling
to fund new medicines, although this has not been taken further
(2). This may be because such considerations will be complex
given for instance free movement of services and goods in Europe
(196) and potentially difficult within the confines of external
reference pricing despite its many challenges and concerns (111,
197–199).
There are also concerns that such strategies may decrease
transparency between pharmaceutical companies and health
authorities (200), that such arrangements amount to developed
countries subsidizing medicines for LMICs, and that companies
may not have strong incentives to re-evaluate tier prices in the
absence of competition (195). There may though be situations
where tiered pricing is an option to address affordability issues
for new valued medicines; however, there is a need to stimulate
competition in the long term to ensure continued availability and
affordability of new medicines (2, 195).
Other approaches include LMICs taking advantage of public
health intellectual property flexibilities, and LMICs working with
pharmaceutical companies and others to make sure essential
medicines are made routinely available (30, 195, 201). Private
public partnerships between government and the pharmaceutical
industry are growing among LMICs to decrease costs and
increasing availability. In South Africa, the Biovac Institute will
in the future locally manufacture the hexavalent vaccine, which
protects against six life-threatening infections, with an estimated
medium term saving of 15% (202, 203). Partnerships are also
growing in Brazil to increase access to biosimilars and medicines
for HIV (204, 205). In addition, pharmaceutical companies are
making medicines for patients with NCDs available for as little as
US$1/patient/ month to address issues of affordability (9). This
is happening in Kenya, and we will be monitoring the findings
(105, 206). Janssen has also recently signed an agreement to lower
the prices of medicines for TB in South Africa (106). It is likely
such arrangements will grow in the future.
Alongside this, there is likely to be greater cross-border and
regional collaborations among European countries to lower the
prices of new medicines during negotiations especially for cancer
and orphan diseases (46, 111, 168–170, 207).
Valuing new cancer medicines
There have been initiatives by different stakeholder groups,
including different cancer organizations, to try to quantify the
level of benefit of new cancer medicines given ongoing funding
concerns and little correlation to date between reimbursed
prices and increased effectiveness (25, 208–212). However, there
have been concerns with the use of surrogate markers such as
response rates and disease free survival especially in patients
with solid tumors (25, 39, 40, 179, 180). This has resulted
in proposals to introduce more stringent assessment criteria
such as minimal improvements in survival rates before granting
premium prices for new cancer medicines (25, 34, 42, 213–
216). Suggested minimal improvements include 3 to 6 months
additional survival compared with current standards, although
others have suggested less (215, 217). Alongside this, looking
more critically at important factors for patients, and critically
assessing the evidence alongside requested prices for decision
making if only surrogate endpoint data is available (213, 216).
Having said this, EUnetHTA believe surrogate endpoints in
oncology are acceptable for accelerated or conditional marketing
authorization approval; however, their utility for reimbursement
and funding decisions will vary across countries (218).
There are also increased calls for moderation in the pricing
of new cancer medicines as the continued increase in requested
prices is becoming unsustainable (219–221). Such calls are
enhanced by currently limited correlation between the degree
of spend on cancer care and overall survival rates (222, 223).
This is part of a general considerations on issues of fairer pricing
with for instance the WHO recently launching the “Fair Price
Forum” (158). There are also calls for proactive engagement by
health authorities and governments in determining the potential
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initial price for a new cancer medicine based on the perceived
health gain vs. current standards and improving negotiation skills
during pricing discussions (111). Such discussions could also
include whether the definition for orphan disease status needs
refining into those medicines for genuine orphan diseases vs.
companies using orphan disease status to increase requested
prices for their new oncology medicines, which has resulted in
very high prices especially for combinations (47).
Alongside this, there needs to be greater scrutiny regarding the
existing spend on cancer medicines with greater understanding
of opportunity costs across the different components of cancer
care, as well as encouraging greater involvement of NGOs and
others in helping to fund cancer medicines especially in LMICs,
similar to the situation for treatments for HIV/ AIDS, cancer and
NCDs (10, 105, 107, 128, 224, 225).
There also needs to be greater re-evaluation of reimbursed
prices, including potential discounts, as more standardmedicines
in oncology become available as low cost generics or biosimilars.
This is increasingly essential to fund increased volumes and
new valued oncology medicines to improve care within finite
resources.
Post Launch Activities
Post launch activities (Figure 1) include (i) monitoring the
effectiveness and safety of new medicines in routine clinical
practice using information in either patient registries or
Electronic Health Records, (ii) evaluating ongoing MEAs and
(iii) monitoring physicians prescribing against agreed guidance
or quality indicators (3, 116, 141, 148).
Examples of studies monitoring the effectiveness and/ or
safety of newmedicines, as well as monitoring prescribing against
agreed guidance, are contained in Table 2.
It is likely that the use of real world data (RWD) will
grow to support reimbursement and funding decisions with
increasing use of electronic health records (183), enhanced
in Europe through initiatives such as GetReal, which is a
3-year project involving the Innovative Medicines Initiative
(IMI), pharmaceutical companies, academia, HTA agencies,
payers, regulators, patient organizations as well as commercial
organizations in generating patient level data (184). This is
particularly important with medicines for orphan diseases where
only limited data may be available at launch. However, ownership
of RWD is a critical issue (108).
It is also likely that we will see greater historical data to help
appraise the role and value of new medicines for orphan diseases
with the full implementation of the European Reference Network
(50, 52).
There are also ongoing activities particularly among LMICs
to improve the activities and influence of drug and therapeutic
committees (DTCs) to enhance the rational use of medicines
especially in their hospitals as this can be variable (126, 240, 241).
These activities can be enhanced by introducing legislation and
other activities to increase the role of DTCs as currently seen
in South Africa (240, 242). This builds on activities among
Western countries to improve the rational use of medicines
generally and post launch, including the interface (125). There is
also ongoing research within Stockholm, Sweden, to document
the impact of DTCs on influencing the use of new medicines
given ongoing resource pressures. Overall Sweden, including
Stockholm Country Council, has been one of the leading
countries to co-ordinate such activities to improve the managed
entry of new medicines, providing direction to other countries
(136). This will continue.
Norway also provides an example of hospitals coming
together for joint pricing negotiations for new and established
medicines to improve affordability, for example low prices are
now being paid for infliximab biosimilar and medicines for
cancer (243). As mentioned, we are also seeing a growth in
cross-border and regional collaborations to improve pricing
negotiations for new medicines, which will continue (46, 168,
169, 207).
There is also ongoing research among European payers and
their advisers to seek additional ways to enhance the rational
use of medicines to help ensure available funds are prioritized
for valued medicines. This together with the implications will be
reported in future publications to further improve rational use.
Care is needed though when introducing new initiatives as
expectations may not always be realized. This was seen in both
Abu Dhabi and Korea when introducing policies to enhance
competition and use of generics within their healthcare systems
(244, 245).
Multiple Criteria Decision Analysis (MCDA)
Tools Especially for Patients With Cancer
and Orphan Diseases
We are also seeing the growth in MCDA tools as a potential
way to enhance structured, transparent and explicit approaches
to reimbursement and funding decisions, resulting in guidance
from different groups (33, 71, 246, 247). This also includes
guidance to LMICs on potential ways to implement MCDAs to
enhance transparency and standardization in funding decisions
for new medicines (248). MCDA is an extension of decision
theory that supports decisionmakers who havemultiple (possibly
conflicting) objectives by decomposing the decision objectives
into key criteria (249). MCDA does not replace judgement, but
rather identifies, collects and structures the information required
by those making judgements to support the deliberative process.
Several public agencies and health insurers (such as G-BA in
Germany, NICE in England and Wales and PBAC in Australia)
are already using or proposing MCDA approaches in healthcare
decision making, including prioritization of resources and
activities (e.g., in Thailand), given concerns with uncertainty and
rising prices, and this is likely to grow (247, 250–254). In most
MCDAs, criteria such as disease severity, likely health outcomes
including the safety profile, effectiveness, likely total costs/ budget
impact, and activities surrounding the implementation of the
new medicine, are mostly used to enhance decision making in
addition to the quality of the evidence (33, 69, 255). Overall,
it is increasingly believed MCDA can be used to support the
HTA process; however, methodological challenges still remain
(254, 256).
There are also ongoing initiatives, such as in the Netherlands
and the UK, to use structured deliberative MCDA as opposed
Frontiers in Public Health | www.frontiersin.org 9 December 2018 | Volume 6 | Article 328
Godman et al. Access to New Medicines
TABLE 2 | Examples of post launch studies to improve future care provision.
Country/Region and
disease area
Summary of studies
Belgium – patients with
NVAF (226)
• The appropriateness of prescribing of either rivaroxaban or dabigatran in patients with non-valvular atrial fibrillation (NVAF) was
evaluated, with the primary outcome measure being the prevalence of inappropriate prescribing
• 69 patients were evaluated; 23% had one with an additional 26% more than one inappropriate criterion. The most frequent
inappropriate criteria were inappropriate choices, wrong dose, and impractical mode of administration (26–28%)
• The authors concluded that reinforcing education of health care professionals and patients is needed to improve future care
Catalonia (Spain)
(227)—dabigatran in atrial
fibrillation
• The study showed concerns with the appreciable number of patients over 80 years old receiving dabigatran for atrial fibrillation and
not receiving the recommended dose
• Renal function was also not being recorded in an appreciable number of patients (30%) and concerns that 17% of patients had
previous ischemic heart disease which is a contraindication to dabigatran
• Further educational initiatives are being planned to address this
Italy and
Sweden—Dronedarone
(228, 229)
• The authors evaluated how reimbursement of dronedarone impacted on the utilization of other antiarrhythmic drugs
• In Sweden, the launch of dronedarone resulted in increased prescribing of antiarrhythmics without a variation in amiodarone use. It
was different in Italy (Emilia Romagna Region), where the launch of dronedarone did not influence prescribing overall of antiarrhythmics
or amiodarone
• The authors believed limited impact on amiodarone prescribing was probably due to caution among physicians toward dronedarone
in line with regulatory recommendations and safety warnings
• These findings have been used to further develop a model in Sweden to evaluate the effectiveness, safety, and cost of new
medicines in routine clinical care. This sequential model, using electronic health records and administrative health databases, can
help to optimize the introduction of new medicines, providing direction to other regions and countries
Sweden ARTIS (Anti
Rheumatic Therapies in
Sweden) (230, 231)
• This comprehensive registry study has shown that (i) patients with rheumatoid arthritis treated with biological drugs are not at
increased risk of invasive melanoma; (ii) patients with rheumatoid arthritis selected for TNF alpha inhibitors are not at increased
overall risk for cancer but have an increased relative risk of invasive melanoma
• The authors concluded that given the small increase in absolute risk, there is no shift in the overall risk-benefit balance of TNF alpha
inhibitors in clinical practice; however care needs to be exercised in patients at high risk of melanoma
Italy—GISEA registry (232) • Evaluation of 4-year retention rates of TNF alpha inhibitors among patients with long standing rheumatoid arthritis (RA)
• The authors found that persistence was overall lower than 50%, with etanercept having the best retention rate
• The principal positive predictor of patient adherence to TNF alpha inhibitors was the concomitant use of methotrexate
Brazil—Comparative
effectiveness of adalimumab
or etanercept for
rheumatoid arthritis (233)
• This open prospective cohort study sought to evaluate the effectiveness and safety among patients with rheumatoid arthritis (RA)
within the Brazilian Public Health System using a variety of different outcome measures
• This study showed similar effectiveness between adalimumab and etanercept, with both treatments well-tolerated
• Both treatments were more effective in RA patients who had better functionality at the start of treatment and had spent longer in
education
Registry for patients with
psoriasis including Psocare
(Italy), Biobadaderm (Spain),
and Clalit Health Services
(Israel) (234)
• The objective of this large database study in Italy was to quantify the risk of infections including serious infections in patients prescribed
TNF alpha inhibitors compared with non-biological therapies including methotrexate and cyclosporine
• Overall 17,739 patients were included and 23,357.5 person-years of follow-up
• The authors concluded that in current clinical practice, treatment with TNF alpha inhibitors was not associated with a higher risk of
serious infections than treatment with non-biologic therapies such as methotrexate and cyclosporine
Brazil—Clinical effectiveness
of different types of insulin in
patients with Type 1
Diabetes (235)
• 580 patients were enrolled using data from the Brazilian National health Services database in Minas Gerais (Region in Brazil)
• Overall there was no clinically significant difference in HbA1c levels between insulin glargine and NPH insulin
• This was illustrated by the frequency of glycemic control being similar between the two groups and no statistically significant difference
between controlled and still uncontrolled patient groups for all analyzed factors
• The authors concluded there were limited clinical difference between the two insulins in routine clinical care, and this did not justify
current appreciable price differences between the two insulins in Brazil
Sweden—Anti-Obesity
medicines (236)
• Analysis of patient level data assessing the characteristics and utilization of patients prescribed various weight-loss drugs in Sweden
showed there was limited persistence with weight loss treatments in routine clinical practice with over three quarters of patients
continuing their treatment for <1 year
• A high percentage of patients (28 to 32%) had a history of depression or antidepressant treatment which is a specific contraindication
for rimonabant
• Over 40% of patients on sibutramine had a history of hypertension and/or cardiovascular disease, which is a contraindication
• Over a third of patients had no documented weight change after treatment
Brazil—Ten year follow up of
kidney transplant patients
receiving either cyclosporine
or tacrolimus (237)
• This study involved 13,811 patients registered with the Brazilian National health Service database
• Overall, a higher risk of graft loss was seen with tacrolimus vs. cyclosporine. Other factors increasing the risk of graft loss included
kidney grafts coming from deceased donors and from more elderly patients, a median period of dialysis > 47 months before
transplantation and a diagnosis of diabetes as the primary cause of chronic kidney disease
• The authors concluded that tacrolimus-based regimens provided poorer outcomes against current beliefs and its use should be
reviewed
Sweden—Effectiveness and
adherence to second
generation DAAs (238)
• This cross-sectional study involved national data from the Prescribed Drug Register and InfCare Hepatitis (quality register)
• 3,447 patients in Sweden were initiated on second generation DAAs for Hepatitis C during 2014-2015
• The estimated overall cure rate was 96%, although there were some variations between genotypes
(Continued)
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TABLE 2 | Continued
Country/Region and
disease area
Summary of studies
• There was a high level of adherence to the introduction protocol (up to 94.2% for drug recommendations and 87% for treatment
eligibility)
• Overall, there was rapid uptake and equal distribution of DAAs in Sweden appreciably improving care for these patients
Adherence to national
antibiotic guidelines in
Namibia (239)
• The study found that the majority of prescriptions (over 60%) complied with national standard treatment guidelines (NSTGs)
• However, compliance rates were lower than national targets (95%) which needs to be addressed. In addition, most prescriptions
were empiric
• There are ongoing moves to improve adherence to guidelines including developing quality indicators. Adherence to guidelines is
also important in ambulatory care to improve future antibiotic use
NB, DAA—Direct acting antivirals.
to the classic algorithmic MCDA in appraising new health
technologies. In this approach, an in-depth consideration of a
broad range of criteria takes place, including a critical assessment
of available evidence. This requires relevant stakeholders to be
explicit about their judgment regarding each criterion, and the
impact on decisions. It is argued that structured deliberative
MCDA improves the quality, consistency and transparency of
decisions, and is likely to be applied more in the future. We
will be monitoring these developments and their implications for
reimbursement and funding decisions for new premium priced
medicines.
It is perhaps not surprising that most MCDAs have been
proposed for medicines for patients with cancer and orphan
diseases given the level of uncertainty surrounding a number
of these medicines, high requested prices, the heterogeneous
nature of key stakeholders, and the emotive nature of the
disease area (2, 67, 68, 72, 257). A number of the suggestions
to improve reimbursement negotiations for new medicines
for orphan diseases followed the controversy surrounding
the reimbursement for enzyme replacement therapy for the
symptomatic treatment of Fabry disease in the Netherlands at
an incremental cost/ quality adjusted life-year of e3.3 million
(37). A similar situation was seen with alglucosidase alfa to
treat Pompe’s disease. The estimated cost/ QALY was e0.3–
0.9 million for the classic form of Pompe’s disease up to e15
million/ QALY for the non-classic form (37). One of the principal
MCDAs that evolved from this experience was the development
of a Transparent Value Framework (TVF) for new medicines
for orphan diseases (258–260) driven by MoCA (Mechanism
for Co-ordinated Access to Orphan Medicinal Products). The
TVF (Table 3) consists of four elements of value together with
the extent to which each criterion is met, with the findings
subsequently used as a possible basis for pricing negotiations
(259, 260).
It must be recognized though that the TVF is a non-
prescriptive and non-binding value framework, which means
that EU member states still have the responsibility for
reimbursement decisions with regard to new medicines for
orphan diseases in their country.
Having said this, the MoCA process is continuing with the
TVF to provide a mechanism for joint discussions in this crucial
area among all key stakeholder groups in Europe (259, 261)
TABLE 3 | The transparent value framework [adapted from (260)].
Criterion Low degree Medium
degree
High degree
Available alternatives/Unmet
Need
Alternatives
are available
and the new
medicine
does not
address areas
of unmet
need
Alternatives
are available
but major
unmet need
still exist
There are
currently no
alternatives
available and
the ned
medicine
addresses
major unmet
need
(Relative) effectiveness—the
degree of net health benefit
relative to alternatives
including no treatment. Net
benefit includes the degree
of health gain including
improved Quality of Life
(QoL) vs. potential side
effects from the new
medicine for orphan
diseases
Incremental Major Curative
Response Rate – based on
clinically relevant endpoints
and time frames
<30% 30–60% >60%
Degree of Certainty—based
on available documentation
(defined as the certainty of
the claim made by the
company)
Promising but
not well-
documented
Plausible Unequivocal
given current disparities in the availability of medicines for rare
diseases across Europe (262). Such developments could also aid
EURORDIS in its objective to have 3 to 5 times more therapies
for rare diseases approved per year than currently by 2025 and
three to five times cheaper to enhance access and affordability
(50). This may be helped by improvements in genomics to aid
diagnosis and discussions around fair pricing, potentially helped
by joint purchasing and pricing negotiations, to re-balance
current disparities in the availability of medicines for orphan
diseases across countries (14, 47, 50, 169, 262). This can start
with early dialogue between all key stakeholder groups as part
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of Horizon Scanning activities (section Pre-launch Activities),
coupled with discussions on registries to improve information
about orphan diseases and new medicines post launch. In
addition, discussions about realistic pricing expectations among
all key stakeholder groups starting pre-launch (49, 50, 263,
264).
Possible Different Models for Financing
New Medicines
New ways of addressing and financing new medicines are also
being discussed given the extent of unmet need. A number
of proposals have been suggested to finance R&D and new
medicines given increasing concerns with issues of access and
affordability (108). These include issues of acceptable value as
well as de-linking the costs of R&D from a medicine’s price,
with basic research currently being predominantly undertaken
in universities or funded by public sources (108, 265–268). De-
linking models have been postulated for new cancer medicines
in addition to new antimicrobials (267, 269). The situation
with antibiotics is especially critical given the scarcity of new
antibiotics in development to combat rising resistance rates
with their appreciable impact on morbidity, mortality, and
costs (270). The Drugs for Neglected Disease Partnership has
been seen as a potential model for future de-linkage activities
(108).
We are also seeing initiatives such as the Triple Helix model
for innovation involving partnerships between universities,
industry and governments (108, 271). An example of this is the
development of new innovations in radiotherapy involving the
Karolinska Institutet in Sweden together with other universities,
private companies, and the government (108).
Potential new approaches also include a combination of push
and pull incentives. Push mechanisms involve for instance direct
investments in basic research and product development (272),
which can include public sector research grants or research
institutions (273). Pull mechanisms provide confidence in future
sales and possible profitability through giving assurance on
potential sales (272). Such approaches can stimulate research
activities leading to the launch of new medicines in areas of need
such as new medicines to treat rare orphan diseases or neglected
diseases (272).
Health Impact Bonds (HIBs) have also been proposed,
implemented for instance by a government determining suitable
health programmes for finance and engaging intermediary
stakeholders to help market potential investment opportunities
(274). The programmes would be administered by healthcare
providers, with external evaluators responsible for monitoring
their progress (274). The first HIB was a program run
in California for patients with asthma based on attaining
over a 2-year period a 30% reduction in emergency room
visits and a 50% reduction in asthma-related hospitalisations
(274).
Additional possibilities include establishing a megafund as a
single financial entity to invest in multiple biomedical projects
(275). The intention is that by having one megafund, which
entails a large portfolio of biomedical projects during different
stages of drug development, the risk associated with attrition
rates can be decreased to improve access and availability of
new medicines. Such approaches have been proposed for new
oncology medicines as well as medicines for rare diseases (275–
277).
Lastly, annuity payments have been proposed for new gene
therapies in view of their requested prices and limited uptake
to date with such costs (47, 109, 278). We are already seeing
companies offering installment payment plans to lung cancer
patients to spread the costs (107).
There is ongoing research among payers and their advisers
in Europe to discuss these and other potential approaches to
improve financing and access to new valued medicines whilst
maintaining sustainability of healthcare systems. This will be
reported in the future.
We are aware that we have principally concentrated on the
perspective of payers and their advisers. However, we believe this
is appropriate especially among European and South American
countries and Korea given their crucial role in the funding and
utilization of new medicines.
CONCLUSIONS
There is continued unmet need for new medicines especially for
disease areas such as cancer, immunological diseases and orphan
diseases. However, there are concerns with ever increasing prices
along with funding increased medicine volumes with growing
rates of patients with infectious diseases and NCDs worldwide.
This requires co-ordinated activities by all key stakeholder groups
to seek to fund new valued medicines whilst maintaining or
attaining universal access to healthcare, with health considered
a goal for all individuals. Co-ordinated activities among payers
have been successful with limiting increases in expenditure in
Europe (279); however, new approaches are now needed given
increasing resource pressures alongside continual unmet need.
A number of approaches have been discussed to help fund
new valuedmedicines overcoming current barriers. This includes
developing new models to optimize the managed entry of new
medicines starting up to 36 months before likely EMA approval
through horizon scanning activities. In addition, more stringent
assessment of the actual role and value of new medicines to
ensure funding is directed to those new medicines that are
the most valued in all or sub-populations, as well as greater
involvement of patients in key areas. This will be closely
monitored. As part of this, we are likely to see continued growth
in MEAs to help with the financing of new medicines although
there are concerns with these including continuing confidential
discounts. This is likely to lead to increased discussions whether
such discounts should continue within public healthcare systems.
There are also likely to be clearer objectives around any proposed
MEAs in the future as well as greater monitoring of their
outcomes, including any administrative financial burden, to
guide future schemes, and this will be followed up in future
research projects.
We are also likely to see new initiatives especially in higher
income countries around MCDAs for new medicines such as the
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TVF for orphan diseases and possibly new cancer medicines.
Ongoing activities with the MoCA and EURODIS will also be
closely monitored to see if this improves access to new medicines
for orphan diseases in the future. Any MCDA for new cancer
medicines are likely to include effectiveness/outcome criteria
given current concerns with surrogate markers and limited
additional overall survival for a number of new cancer medicines.
Alongside this, there is likely to be increasing re-evaluation of
prices and discounts for existing patented medicines, especially
high priced medicines, once the comparators used in the
evaluations become available as low cost generics or biosimilars.
This will also be closely monitored given concerns with
increasing expenditure on cancer medicines and issues of
sustainability.
We are also likely to see continued growth in cross-border and
regional collaborations to enhance pricing negotiations especially
surrounding new medicines for orphan diseases (170). In
addition, greater generation of real world evidence around new
medicines given the continued growth in electronic healthcare
systems to inform future treatment decisions. This will also be
the subject of future research projects involving some of the co-
authors. There will also continue to be ongoing research around
different approaches to the financing of new medicines especially
from the standpoint of payers and their advisers, and we will also
be reporting on this in the near future.
The principal issue for a number of LMICs are concerns
with the availability and access to essential medicines as defined
by the WHO and others. This includes for instance ensuring
increased access to appropriate medicines for patients with NCDs
including cancer as well as enhancing their appropriate use,
which involves enhancing adherence rates where these are a
concern (10, 101, 225). Alongside this, acceleratingmoves toward
universal health care. These are essential first steps before LMICs
actively consider funding new treatments, unless these are funded
by donors such as those for HIV and multidrug resistant TB,
given the limited health gain withmost newmedicines. Alongside
this, instigating improved systemsmanagement to reduce out-of-
stock situations in public healthcare facilities, as well as greater
accountability and transparency in decision making, building on
current initiatives (81, 242). We will also be monitoring this in
the future. We will also see the growth of HTAs among LMICs
evaluating the cost-effectiveness and value for money of new
interventions to improve evidence-based decision-making. This
though will require legislation and policies as well as making
suitable resources available (280).
We are already seeing DTC activities grow in LMICs to
improve the quality and efficiency of prescribing, and this will
continue alongside initiatives to improve physician education
regarding the use medicines. As a result helping to reduce any
inappropriate influence of pharmaceutical company activities
(281). Alongside this, we are likely to see increased activities
to monitor the appropriate use of medicines especially among
LMICs given concerns with inappropriate prescribing leading to
increased costs and for instance higher antimicrobial resistance
rates (239, 240, 242). This is already happening for instance
across Africa (282), and will increasingly include monitoring
of prescribing against national treatment guidelines, and any
other authoritative guidelines, building on current initiatives
(239, 283).
There will also need to be greater scrutiny of the quality of
medicines, especially generics, among a number of LMICs to
improve their acceptance and use.
Moves to introduce fairer prices for medicines, including
potential consortia, will also grow to improve access to key
medicines as LMICs strive toward universal access, and this will
also be the subject of future research projects.
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